American Journal of Dermatological Research and Reviews


Diagnosis and Reporting of Dysplastic (Atypical, Clarks) Nevi – a Reassessment

Review Article of American Journal of Dermatological Research and Reviews Diagnosis and Reporting of Dysplastic (Atypical, Clarks) Nevi – a Reassessment Eric Schloss, M.D., FRCP(C), Clinical Professor1, Jaggi Rao, M.D., FRCP(C), Clinical Professor2, Marianne Hrabok, Ph.D.3 1Dermatology & Dermatopathology, Faculty of Medicine, University of Alberta; 2Dermatology, Faculty of Medicine, University of Alberta; 3Faculty of Medicine, University of Alberta Faculty of Medicine, University of Calgary. This article on dysplastic nevi was compiled and written in August 2004 but never published in a print journal. It is our opinion that now, 15 years later, the same conclusions documented in the initial article still exist. In fact, the further studies and reports strongly support the lack of malignancy (nor evidence of pre-cursors of malignancy) in correctly histologically diagnosed junctional or compound dysplastic nevi and the lack of need of re-excision of these nevi in almost all cases. 1,2,3,4 Keywords: dysplastic, melanoma, pathology ...

Does the site of a Malignant melanoma predict the likelihood of distant metastases

Research Article of American Journal of Dermatological Research and Reviews Does the site of a Malignant melanoma predict the likelihood of distant metastases Mohammed Al Abadie1, Khaleeq-Ur Rehman1, Mohammed Al-Rubaye1, Faris Oumeish1, Veena Shinde1, Abigail Pugh1, Dina Al Abadie2 1Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom; 2Department of Health Promotion and Public Health, University of West London, London, United Kingdom. Introduction: Malignant melanoma is a lethal skin cancer which is on the rise despite increasing education on sun awareness. It is most common in young Caucasian individuals however any age or ethnicity can be affected. Discussion: There are four main types of malignant melanoma which include superficial spreading MM (most common), Nodular (most lethal), Acral lentignous melanoma and Lentigo maligna melanoma. Once it has metastasized the prognosis is poor but new treatments are giving us much better outcomes. Aim: The main aim of this study is to identify which MMs are most likely to metastasize based on the location with the two main groups being above neck and below neck. Methods and results: forty-five patients were included in the study, 37 were below neck and 8 were above neck. Out of the 37 below neck MM patients, none had distant metastases , but 25% of the above neck MM patients had distant metastases. Conclusion: This small study has demonstrated that above neck malignant melanoma is more likely to metastasize than below neck malignant melanoma despite advanced Tumor scores in the below neck subgroup. Keywords: MM (malignant melanoma), SLNB (sentinel lymph node biopsy), metastasis ...

Treatment of Chronic Plaque Psoriasis with Etanercept and Methotrexate

Research Article of American Journal of Dermatological Research and Reviews Treatment of Chronic Plaque Psoriasis with Etanercept and Methotrexate Husam A. Salman1, Fatema A. Al-Jaralla2, Rana K. Obeed3 1Department of Dermatology, College of Medicine, University of Baghdad. Iraqi and Arab Board for Dermatology &Venereology, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq. 2Department of Dermatology, College of Medicine, University of Baghdad, Baghdad, Iraq.3Dermatology Center, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq. Abstract: psoriasis is a chronic multifactorial disease that has negative impact on the patient’s quality of life. Selecting appropriate treatment for each patient must be both effective and relatively safe. Methotrexate and Etanercept are systemic therapies used for moderate – severe chronic plaque psoriasis. Objective: The aim of study is to assess the efficacy of methotrexate and etanercept in the treatment of chronic plaque psoriasis. Patients and Methods: This therapeutic, interventional comparative single centre study was carried out at the Centre of Dermatology and Venereology, Baghdad Teaching Hospital, from January 2015 –July 2017. A total of 62 patients were enrolled; divided into two groups. Group I: Thirty-three patients (23 males and 10 females), their ages ranged between 15 and 65 years mean ±SD 33.13±13.07, received etanercept 50mg twice weekly for 3 months then once weekly thereafter. Group II: Twenty-nine patients (19 males and 10 females), their ages ranged between 15 and 62 years mean±SD 38.16±15.2, received methotrexate 15 mg per week for six months then tapered. Both groups were followed up monthly for 6 months and their PASI score, DLQI, side effect and pictures were recorded. Results: Seven patients defaulted from the study for unknown reason,30 patients completed in etanercept group, while 25 patients completed in methotrexate group. After 12 weeks the PASI score decrease from baseline 19.13±10.67 to 6.38±4.96 and then to 3.34±5.38 after 24 weeks treatment with Etanercept ...

Management of Oro-Cutaneous Manifestations in Behçet disease and Recurrent Oral Aphthosis, review article

Review Article of American Journal of Dermatological Research and Reviews Management of Oro-Cutaneous Manifestations in Behçet disease and Recurrent Oral Aphthosis, review article Khalifa E. Sharquie1, Fatema A. Al-Jaralla2 1Department of Dermatology, College of Medicine, University of Baghdad. Iraqi and Arab Board for Dermatology & Venereology, Baghdad Teaching Hospital, Medical City, Baghdad, Iraq. 2Department of Dermatology, College of Medicine, University of Baghdad, Baghdad, Iraq. Recurrent oral aphthosis is a major health problem affecting 20% of population. Its pathogenesis is not well elucidated, however, it’s considered as part of major criteria of Behçet disease. Many therapies advised to manage these ulcerations in both diseases and most of them are symptomatic, however, in the last decades; some of them have shown therapeutic as well as prophylactic roles. Herein, we review the different aspects of these therapies with emphasis on Iraqi experience. Keywords: Recurrent oral aphthosis, Behçet disease, Management ...

Manuscript Title: The title should be a brief phrase.

Author Information: List full names and affiliation of all authors, including Emails and phone numbers of corresponding author.

Abstract: The abstract should be less than 500 words. Following abstract, a list of keywords and abbreviations should be added. The keywords should be no more than 10. Abbreviation are only used for non standard and long terms.

Introduction: The introduction should included a clear statement of current problems.

Materials and Methods: This section should be clearly described.

Results and discussion: Authors may put results and discussion into a single section or show them separately.

Acknowledgement: This section includes a brief acknowledgment of people, grant details, funds

References: References should be listed in a numbered citation order at the end of the manuscript. DOIs and links to referenced articles should be added if available. Abstracts and talks for conferences or papers not yet accepted should not be cited. Examples Published Papers: 

1. Avinaba Mukherjee, Sourav Sikdar, Anisur Rahman Khuda-Bukhsh. Evaluation of ameliorative potential of isolated flavonol fractions from Thuja occidentalis in lung cancer cells and in Benzo(a) pyrene induced lung toxicity in mice. International Journal of Traditional and Complementary Medicine, 2016; 1(1): 0001-0013. 
2. Vikas Gupta, Parveen Bansal, Junaid Niazi, Kamlesh Kohli, Pankaj Ghaiye. Anti-anxiety Activity of Citrus paradisi var. duncan Extracts in Swiss Albino Mice-A Preclinical Study. Journal of Herbal Medicine Research, 2016; 1(1): 0001-0006.

Tables and figures: Tables should be used at a minimum with a short descriptive title. The preferred file formats for Figures/Graphics are GIF, TIFF, JPEG or PowerPoint.

Publication fee: The authors will be contacted about the publication fee after a manuscript have been accepted.

Proofreading and Publication: A proof will be sent to the corresponding author before publication. Authors should carefully read the proof to avoid any errors and return the proof to the editorial office. Editorial office will publish the article shortly and send a notice to authors with the links of the paper.

The editorial policies in this page are the guidelines of publication process of eSciPub journals. We adhere the following requirements including but not limited to Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE), International Association of Scientific, Technical & Medical Publishers (STM) , and World Association of Medical Editors (WAME). To get more details, please refer to the websites ofCOPE, ICMJE, STM and WAME.

Editors control the quality of publications in eSciPub Journals. Editorial duties may include but not limited to review manuscripts to make sure the submission meet the requirements of Author Guidelines, referee the submissions to right peer reviewers, give comments to improve the quality of manuscripts and decide the acceptance or rejection of manuscripts.

  • Take in charge of searching the members of editorial board and reviewers;
  • Give possible suggestions to improve the quality of the journals of eSciPub;
  • Follow publication ethics;
  • Determine rejection or acceptance of a submission;
  • Search peer reviewers;
  • Communicate authors and reviewers;
  • Answer the questions of authors and reviewers;
  • Recruit authors to publish high quanlity papers in eSciPub journals;

eSciPub may update current policy periodically.

Please feel free to contact our rapid response team if you have any questions. Our customer representative will answer you shortly.

Open Access

American Journal of Dermatological Research and Reviews (ISSN:2638-1893; DOI:10.28933/AJODRR) is a peer reviewed open access journal publishing research manuscripts, review articles, editorials, letters to the editor in Dermatological Research and Reviews (Indexing information).

Peer Review

To ensure the quality of the publications, all submitted manuscripts will be peer-reviewed by invited experts in the field. The decisions of editors will be made based on the comments of the reviewers.

Rapid Publication

Time to first decision: within 2 days for initial decision without review, 18 days with review; Time to publication: Accepted articles will be published online within 2 days, and final corrected versions by authors will be accessible within 5 days.  More details....

Rapid Response Team

Please feel free to contact our rapid response team if you have any questions. Our customer representative will answer you shortly.

American Journal of Dermatological Research and Reviews

Loading